+

WO2008006007A3 - Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis - Google Patents

Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis Download PDF

Info

Publication number
WO2008006007A3
WO2008006007A3 PCT/US2007/072801 US2007072801W WO2008006007A3 WO 2008006007 A3 WO2008006007 A3 WO 2008006007A3 US 2007072801 W US2007072801 W US 2007072801W WO 2008006007 A3 WO2008006007 A3 WO 2008006007A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
cftr
causes increased
sphingolipid synthesis
transduction regulator
Prior art date
Application number
PCT/US2007/072801
Other languages
French (fr)
Other versions
WO2008006007A2 (en
Inventor
Tilla Worgall
Original Assignee
Univ Columbia
Tilla Worgall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Tilla Worgall filed Critical Univ Columbia
Publication of WO2008006007A2 publication Critical patent/WO2008006007A2/en
Publication of WO2008006007A3 publication Critical patent/WO2008006007A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods and compositions for treating cystic fibrosis and P. aeruginosa infections by administering a therapeutic amount of one or more agents that inhibit de novo sphingolipid synthesis or recycling pathways.
PCT/US2007/072801 2006-07-03 2007-07-03 Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis WO2008006007A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81835106P 2006-07-03 2006-07-03
US60/818,351 2006-07-03

Publications (2)

Publication Number Publication Date
WO2008006007A2 WO2008006007A2 (en) 2008-01-10
WO2008006007A3 true WO2008006007A3 (en) 2008-10-30

Family

ID=38895458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072801 WO2008006007A2 (en) 2006-07-03 2007-07-03 Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis

Country Status (1)

Country Link
WO (1) WO2008006007A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
ITFE20080032A1 (en) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero ANTI-INFLAMMATORY EFFECT OF MIGLUSTAT CELLULE OF BRONCHIAL EPITHELIUM
EP2906570A4 (en) * 2012-10-15 2016-06-08 Yeda Res & Dev USE OF SPHINGOID LENGTH CHAINS AND THEIR ANALOGUES IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS
EP3171860B1 (en) 2014-07-25 2024-12-11 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2020011744A2 (en) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011745A2 (en) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
IL260690A (en) 2018-07-19 2018-12-31 Yeda Res & Dev Sphingosine analogs and use thereof against bacterial lung infections
EP3887522A1 (en) * 2018-11-29 2021-10-06 University of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197656A1 (en) * 2004-03-02 2007-08-23 Stan Kubow Compositions and methods for preventing or treating an inflammatory response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197656A1 (en) * 2004-03-02 2007-08-23 Stan Kubow Compositions and methods for preventing or treating an inflammatory response

Also Published As

Publication number Publication date
WO2008006007A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008006007A3 (en) Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis
WO2007002559A8 (en) Pyrazole based lxr modulators
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
IL189178A0 (en) Thiazolyl derivatives and pharmaceutical compositions containing the same
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2005046575A3 (en) Amino acid prodrugs
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
UA92641C2 (en) Pharmaceutical composition comprising amlodipine and losartan
HK1138586A1 (en) Modulators of cftr cftr
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007053844A8 (en) Compositions and methods for treating inflammatory disorders
UA93380C2 (en) 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
WO2008070268A3 (en) Pharmaceutical compositions
GB2466912A (en) Compositions and methods for treating lysosomal disorders
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2007117544A3 (en) Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses
WO2006132928A3 (en) Methods and compositions for treating inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840348

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840348

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载